FAK-IN-7是一种 FAK 抑制剂 (IC50 = 11.72 µM)，具有良好的抗增殖活性，可用于癌症研究。

FAK-IN-10是一种 Focal Adhesion Kinase (FAK) 抑制剂，在癌症细胞迁移和侵袭的研究中表现出潜力。

Batatasin III是一种芪类化合物，通过抑制上皮间质转化 (EMT) 和 FAK-AKT 信号通路来抑制癌细胞的迁移和侵袭，具有抗癌活性，适用于肿瘤转移和侵袭相关的研究。

Conteltinib (CT-707)是一种多激酶抑制剂，靶向 FAK、ALK 和 Pyk2，其中对 FAK 的抑制作用显著，IC50 为 1.6 nM。

Ifebemtinib (BI 853520)是一种口服活性粘附斑激酶 (FAK) 抑制剂，对癌细胞具有抗增殖活性。

GSK2256098, is a focal adhesion kinase-1 (FAK) inhibitor with potential antiangiogenic and antineoplastic activities.

PND-1186 is a potent FAK inhibitor with IC50 of 1.5 nM.

PF-431396 is dual focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (PYK2) inhibitor (IC50 values are 2 and 11 nM respectively), PF-431396 has a Kd value of 445 nM for BRD4.

PF-573228 是一种有效且选择性的 FAK 抑制剂，对纯化的重组 FAK 催化片段的 IC50 值为 4 nM。

PF-562271 besylate (VS-6062) 苯磺酸盐是一种高效的 ATP 竞争性、可逆性 FAK 和 Pyk2 激酶抑制剂，对 FAK 的 IC50 为 1.5 nM，对 Pyk2 的 IC50 为 13 nM。

Narmafotinib（AMP-945）是一种针对黏着斑激酶（FAK）的抑制剂，其KD为0.21 nM。Narmafotinib在MDA-MB-231细胞中抑制了397Y-FAK的自磷酸化，IC50为7 nM，并且表现出低细胞毒性（IC50 = 2.7 μM，MDA-MB-231细胞）。

Defactinib（VS-6063；PF-04554878）是一种新型FAK抑制剂，表现出潜在的抗血管生成和抗肿瘤特性。

Y15 is a small molecule FAK phosphorylation inhibitor which specifically block phosphorylation of Y397-FAK and total phosphorylation of FAK.

YH-306是一种通过抑制FAK信号通路来抑制结直肠癌生长和转移的抗肿瘤剂，能显著抑制癌细胞迁移、侵袭，诱导细胞凋亡，并抑制相关的信号分子如PI3K和MMPs的表达。

PF-562271（VS-6062）是一种高效、ATP竞争性和可逆的FAK和Pyk2激酶抑制剂，IC50值分别为1.5 nM和13 nM。

Masitinib is an inhibitor for Kit and PDGFRα/β with IC50 of 200 nM and 540 nM/800 nM, weak inhibition to ABL and c-Fms.

NVP-TAE 226 is a potent FAK inhibitor with IC50 of 5.5 nM, modestly potent to Pyk2 (IC50=3.5 nM) and 10- to 100-fold less potent against InsR, IGF-1R, ALK, and c-Met.

CEP-37440 is a potent and selective Dual FAK/ALK inhibitor with IC50 s of 2.3 nM (FAK) and 120 nM (ALK cellular IC50 in 75% human plasma).

Fangchinoline is an isolate of Stephania tetrandra and has anticancer activity through induction of G1 arrest in breast cancer cells.

CTX-0294885 is a bisanilino pyrimidine and exhibits inhibitory activity against a broad range of kinases in vitro, further developed into a Sepharose-supported kinase capture reagent. CTX-0294885 is a broad spectrum kinase inhibitor that inhibited FAK, FLT3, JAK2, JAK3, Src, Aurora kinase A, and VEGF receptor 3 (IC50s = 4, 1, 3, 28, 2, 18, and 3 nM, respectively) in an initial screen.